Related by context. All words. (Click for frequent words.) 66 CVD mortality 65 advanced adenoma 65 hemoglobin A1c levels 65 locoregional recurrence 65 carotid IMT 65 HbA 1c levels 65 glycated hemoglobin levels 65 multivariable analysis 65 HbA1C levels 64 colorectal adenoma 64 attain statistical significance 64 nonfasting triglyceride levels 64 MMSE scores 64 advanced adenomas 64 autonomic dysfunction 64 multivariate analyzes 64 nondiabetic patients 64 homocysteine concentrations 63 elevated ALT 63 neurodevelopmental impairment 63 β blockers 63 serum estradiol 63 PSADT 63 coronary calcification 63 Hb A1C 63 definite stent thrombosis 63 biochemical recurrence 63 serum lipid levels 63 hip BMD 63 BMI z 63 HbA 1c 63 perioperative mortality 63 highest tertile 63 mL/min/#.# m 2 62 P = .# 62 MMSE score 62 intima media thickness 62 arterial thromboembolic events 62 lowest tertile 62 multivariate adjustment 62 Ishak fibrosis score 62 LV dysfunction 62 postoperative mortality 62 albumin excretion 62 periprocedural 62 HbA1c levels 62 baseline HbA1c 62 HOMA IR 62 % CI #.#-#.# [003] 62 mmol l 62 CHD mortality 62 serum calcium 62 serum concentrations 62 thyrotropin levels 62 tertiles 62 PASI scores 62 subclinical hyperthyroidism 62 univariate analysis 62 serum uric acid 62 elevated triglyceride levels 62 echocardiographic parameters 62 pCR 61 hydroxyvitamin D levels 61 coinfected patients 61 odds ratios ORs 61 potential confounders 61 morphometric vertebral fractures 61 inflammatory biomarkers 61 covariates 61 EDSS scores 61 troponin T 61 sociodemographic factors 61 serum creatinine levels 61 recurrent venous thromboembolism 61 liver transplant recipients 61 mcg QD 61 multivariable adjusted 61 MetS 61 adiponectin concentrations 61 leukocyte count 61 beta blocker therapy 61 thrombocytopenic 61 CC genotype 61 oxycodone CR 61 nonfatal MI 61 fasting insulin 61 NNT = 61 intact parathyroid hormone 61 serum vitamin D 61 systolic dysfunction 61 multivariate regression analysis 61 nonobese 61 tertile 61 perioperatively 60 postintervention 60 postoperative complication 60 cTnT levels 60 platelet reactivity 60 confidence interval #.#-#.# 60 diastolic blood pressures 60 psychiatric comorbidity 60 pT3 60 multivariate Cox 60 recurrent VTE 60 systolic function 60 Baseline characteristics 60 tHcy 60 carotid stenosis 60 serum calcium levels 60 p = NS 60 glycosylated hemoglobin levels 60 serum urate 60 nadroparin 60 tipranavir r 60 Kaplan Meier analysis 60 elevated LDH 60 multivariable analyzes 60 Erythropoietic therapies may 60 TEAEs 60 reinfarction 60 KIF6 carriers 60 mIU L 60 obstructive coronary artery 60 achieved ACR# 60 preintervention 60 % CI #.#-#.# [008] 60 highest quintile 60 symptomatic VTE 60 hormone receptor negative 60 serum IGF 60 systolic BP 60 CR nPR 60 baseline serum creatinine 60 antiretroviral naïve 60 preoperative chemotherapy 60 moderate renal impairment 60 endometrial thickness 59 baseline LDH 59 serum PTH 59 nonfasting triglycerides 59 ejection fractions 59 T2DM 59 macrovascular events 59 MACCE 59 biochemical relapse 59 lipid lowering medications 59 Kaplan Meier estimates 59 dysglycemia 59 % Confidence Interval 59 plasma homocysteine 59 ALT elevation 59 elevated serum creatinine 59 inhospital 59 myocardial infarctions MIs 59 SHBG levels 59 unstable angina pectoris 59 ipsilateral stroke 59 preoperative PSA 59 nmol l 59 noncardiac 59 histologic subtype 59 hsCRP levels 59 alanine aminotransferase ALT 59 adenoma recurrence 59 NIHSS score 59 ATACAND 59 MELD scores 59 sociodemographic characteristics 59 virologic failure 59 lymphocyte count 59 metabolic parameters 59 thromboembolic complications 59 Hb A1c 59 confidence intervals CIs 59 complete cytogenetic response 59 lipid lowering agents 59 CHD CVD 59 ECOG PS 59 NYHA functional class 59 posttransplant 59 urinary albumin excretion 59 contralateral breast 59 comorbid depression 59 corticosteroid dose 59 elevated hsCRP 59 A1c levels 59 Cystatin C 59 deep venous thromboses 59 seropositivity 59 Stent thrombosis 59 perioperative complications 59 NHANES III 59 colorectal neoplasia 59 Subgroup analyzes 59 hemoglobin A1c HbA1c 59 prednisone prednisolone 59 univariate 59 #ng/ml 59 nonfatal myocardial infarction 59 Endothelial function 59 incidence ≥ 59 underwent coronary angiography 59 aged ≥ 59 serum PSA 59 albumin excretion rate 59 PCWP 59 habitual snoring 59 nonvertebral fractures 59 pmol L 58 femoral neck fracture 58 HER2 expression 58 intraobserver 58 de ath 58 creatinine ratio 58 elevated CRP 58 prostate cancer CaP 58 comorbidities 58 posttreatment 58 nonfatal stroke 58 postoperative AF 58 NSTE ACS 58 IV bisphosphonates 58 cranial irradiation 58 angiographic outcomes 58 MADRS score 58 estimated GFR 58 PANSS scores 58 oxygen desaturation 58 SUVmax 58 NYHA class 58 elevated fasting glucose 58 Operative mortality 58 glycosylated hemoglobin HbA1c 58 nondiabetic 58 thrombotic events 58 FluCAM arm 58 folate concentrations 58 adjunctive placebo 58 urinary albumin 58 % CI #.#-#.# [006] 58 CLA supplementation 58 univariate analyzes 58 % CI #.#-#.# [007] 58 genotypic resistance 58 TT genotype 58 clinically insignificant 58 EDSS score 58 multiple logistic regression 58 hemoglobin concentration 58 URTI 58 angiographic restenosis 58 nonvertebral fracture 58 extracapsular extension 58 paclitaxel eluting stents 58 HbA1C 58 spirometric 58 laboratory abnormalities 58 QTcF 58 K ras mutations 58 intracerebral haemorrhage 58 neurocognitive function 58 initiating antiretroviral therapy 58 KRAS mutant tumors 58 recurrent ischemia 58 IPAH 58 graft occlusion 58 distant metastasis 58 statistically significant predictor 58 confidence interval CI 58 colorectal cancer incidence 58 beta carotene supplementation 58 DAS# CRP 58 nodal metastases 58 affective psychosis 58 plasma cortisol 58 FeNO 58 diastolic pressures 58 virological response 58 triacylglycerol concentrations 58 oral antidiabetic medication 58 CrCl 58 ARB telmisartan 58 diastolic BP 58 desvenlafaxine succinate 58 polyp recurrence 58 fasting serum 58 Fasting blood glucose 58 x ULN 58 p = .# [002] 58 death reinfarction 58 NATRECOR ® 58 QTc prolongation 58 dalteparin 58 poor metabolizers 58 interquartile range 58 BRCA1 mutation carriers 58 dietary folate intake 58 seroconverted 58 PSA nadir 58 eosinophil count 58 systemic embolism 58 Triglyceride levels 58 lipid lowering therapy 58 subclinical atherosclerosis 58 SCr 58 statistical significance p 58 FDA defined valvulopathy 58 squamous histology 58 Calcium intake 58 antiphospholipid antibodies 58 CYP#D# genotype 58 coronary stenosis 58 NPH insulin 58 progression TTP 58 thyroid carcinoma 58 Postoperatively 58 prevalences 58 baseline CD4 58 logistic regression analysis 58 undetectable HBV DNA 58 prospectively defined 58 latent celiac disease 57 liver histology 57 dapagliflozin plus 57 hypopneas 57 haemorrhagic stroke 57 MGUS 57 CI #.#-#.# [002] 57 radiochemotherapy 57 lipid profiles 57 transferrin saturation 57 tumor histology 57 shorter telomere length 57 Complication rates 57 LV ejection fraction 57 elevated LDL cholesterol 57 overt nephropathy 57 timepoints 57 fasting glucose levels 57 pg ml 57 Postoperative complications 57 #.#/#.# mmHg [001] 57 atrophic gastritis 57 nonsignificant 57 QALE 57 apnea hypopnea index 57 neurologic outcomes 57 prolactin elevation 57 alanine aminotransferase 57 HIV HCV coinfected 57 μmol L 57 #.#ng/ml 57 myocardial infarctions 57 Univariate analysis 57 blood glucose concentrations 57 Crohn Disease Activity 57 euthymic patients 57 serum folate 57 #OHD levels 57 thyroid hormone levels 57 mmHg diastolic 57 leukopenia 57 reach statistical significance 57 biopsy Gleason 57 inhospital mortality 57 UPDRS scores 57 non fasting triglycerides 57 SGRQ 57 specific antigen PSA 57 distant metastases 57 carotid artery thickness 57 impaired glucose metabolism 57 transaminase elevations 57 fosamprenavir 57 warfarin dosage 57 serum GGT 57 aminotransferases 57 T1DM 57 plasma homocysteine levels 57 serous ovarian cancer 57 HSCT 57 serum testosterone 57 EpCAM expression 57 prognostic variables 57 fragility fracture 57 Kaplan Meier curve 57 colorectal polyp 57 UPDRS motor 57 urate levels 57 serum ALT 57 elevated bilirubin 57 rimonabant #mg 57 renal impairment 57 overt hypothyroidism 57 Secondary endpoints included 57 carotid artery narrowing 57 depressive symptomatology 57 CCyR 57 NATRECOR R 57 renal insufficiency 57 HDL LDL ratio 57 hematologic toxicity 57 pulmonary capillary wedge 57 undergoing radical prostatectomy 57 relapsed MM 57 hypertensives 57 systolic blood pressures 57 distal colon cancer 57 renal cell carcinomas 57 severe exacerbations 57 microbiological eradication 57 cardio respiratory fitness 57 subclinical hypothyroidism 57 comorbid conditions 57 serum selenium 57 nonischemic 57 carotid intima media 57 Thal Dex 57 binary restenosis 57 nondiabetics 57 nonmetastatic 57 lignan intake 57 HBeAg seroconversion 57 atrioventricular block 57 hemorrhagic complications 57 octreotide LAR 57 antibody titer 57 fructosamine 57 serum phosphate 57 serum urate levels 57 bioavailable testosterone 57 statistically significant p = 57 events MACE 57 irbesartan 57 familial clustering 57 resected pancreatic cancer 57 ductal cancer 57 KRAS mutations occur 57 comorbid illnesses 57 ximelagatran 57 Pharmacokinetic parameters 57 HRQoL 57 perioperative morbidity 57 detectable HCV RNA 57 familial aggregation 57 isolated systolic hypertension 57 left ventricular systolic 57 node metastases 57 logistic regression model 57 postoperative chemotherapy 57 TMP SMX 57 #mg dose [002] 57 mIU ml 57 renal dysfunction 57 leukocyte counts 57 ADCS CGIC 57 Index CDAI 57 #mmHg [002] 57 advanced neoplasia 57 mild renal insufficiency 57 antihypertensive medication 57 QIDS SR 57 plasma triglycerides 57 PON1 activity 57 carotid plaques 57 clinico pathological 57 loop diuretics 57 lumbar spine BMD 57 Fasting glucose 57 lopinavir r arm 57 normotensive 57 revascularization procedures 57 triglyceride concentrations 57 mg/m2 dose 57 antihypertensive therapy 57 thromboembolic events 57 ABCB1 57 lipid lowering drugs 57 clinicopathological 57 cardiorespiratory fitness 57 REYATAZ r arm 57 postoperative delirium 57 estimated glomerular filtration 57 PRADAXA #mg 57 contralateral breast cancer 56 hematological parameters 56 sUA 56 SGPT 56 radical prostatectomy RP 56 Y BOCS 56 sociodemographic variables 56 serum BDNF 56 multivariate logistic regression 56 urine albumin 56 ischemic cardiomyopathy 56 lobular cancer 56 secondary efficacy endpoint 56 psychiatric comorbidities 56 underwent resection 56 eGFR 56 calculated creatinine clearance 56 benazepril 56 CYPHER Stent 56 parous women 56 adenotonsillectomy 56 N telopeptide 56 hormone receptor status 56 hemoglobin concentrations 56 cardiovascular mortality 56 confounding variables 56 FOLFOX4 56 nondepressed 56 alteplase 56 glomerular filtration rate 56 atorvastatin #mg 56 Multivariate analysis 56 experienced virologic failure 56 paricalcitol 56 plasma lipids 56 pre eclamptic 56 CIN3 56 perimenopausal women 56 μg dL 56 plasma leptin 56 diastolic function 56 CYP#D# inhibitor 56 cerebrovascular accidents 56 stent thromboses 56 HbA 1C 56 atypical hyperplasia 56 glucose homeostasis 56 cytopenias 56 ALT AST 56 prospectively evaluated 56 Plasma concentrations 56 conditional logistic regression 56 atherogenic dyslipidemia 56 PLX STROKE targeting 56 recurrent wheezing 56 HDRS 56 diameter stenosis 56 atheroma volume 56 elevated transaminases 56 Atkins dieters cardiovascular 56 gallstone disease 56 ACCORD Lipid 56 euthyroid 56 flutamide 56 glycated hemoglobin HbA1c 56 plasma folate 56 insulin detemir 56 median PFS 56 virologically 56 prespecified secondary 56 residual confounding 56 oral Hycamtin 56 logistic regression models 56 DES implantation 56 lymphocytosis 56 femoral neck BMD 56 EBRT 56 elevated creatinine 56 hepatic fat 56 severe renal impairment 56 macrovascular disease 56 Subgroup analysis 56 lipid levels 56 p = #.# [003] 56 BENICAR HCT 56 hepatorenal syndrome 56 ALT flares 56 fasting plasma glucose FPG 56 intravesical therapy 56 myocardial infarction stroke 56 β blocker 56 VaD 56 adjuvant tamoxifen 56 extrapyramidal symptoms 56 coronary revascularization 56 postmenopausal hormones 56 titrated glipizide 56 myocardial infarction MI 56 venlafaxine XR 56 oral prednisolone 56 aspartate aminotransferase AST 56 conjugated equine estrogen 56 ghrelin concentrations 56 serum aminotransferase levels 56 lymph node metastasis 56 serum testosterone levels 56 IOP lowering 56 DAS# scores 56 serum sodium levels 56 CP CPPS 56 glycated hemoglobin 56 HRQOL 56 nonsignificant difference 56 serum folate concentrations 56 gestational hypertension 56 Primary endpoints 56 serum parathyroid hormone 56 hepatic cirrhosis 56 Breslow thickness 56 SLNB 56 gastric cardia 56 TNF antagonist 56 covariate 56 chlamydial infection 56 arterial oxygen saturation 56 hyperglycaemia 56 multivariable adjustment 56 adverse cytogenetics 56 clinicopathological features 56 Serum creatinine 56 seminal vesicle invasion 56 hypovitaminosis D 56 leucopenia 56 fasting glucose 56 lymphocyte counts 56 revascularizations 56 non aspirin NSAIDs 56 resynchronization therapy 56 left ventricular diastolic 56 pyrexia mucositis sepsis febrile 56 cerebral infarction 56 virologic suppression 56 tapentadol ER 56 seroprotection 56 abacavir lamivudine 56 Viral load 56 nonpregnant women 56 cardiovascular morbidity 56 CI -#.# 56 serum potassium 56 creatinine clearance 56 Chlamydia infection 56 aneurysmal subarachnoid hemorrhage 56 lipid parameters 56 acute myocardial infarctions 56 HNSCC 56 #.#mmol L [002] 56 pulmonary exacerbations 56 NNRTI resistance 56 radioiodine therapy 56 axillary node 56 atherosclerotic renal artery stenosis 56 baseline Hb 56 prednisone prednisolone plus 56 BCG vaccinated 56 #mg/dL [001] 56 hypophosphatemia 56 prolonged QT interval 56 CARDIA study 56 antihypertensive medications 56 TNF blocker therapy 56 gestational diabetes mellitus GDM 56 thromboembolism 56 postoperative radiotherapy 56 depressive symptom 56 postdischarge 56 metformin monotherapy 56 subgroup analyzes 56 Homocysteine levels 56 hsCRP 55 pretest probability 55 neurologic complications 55 pT2 55 neurodevelopmental outcome 55 nonselective NSAIDs 55 histological subtype 55 undergone radical prostatectomy 55 Flu Cy 55 HIV uninfected 55 moderate hepatic impairment 55 axillary node dissection 55 hypertension dyslipidemia 55 Univariate 55 intracranial atherosclerosis 55 affective psychoses 55 recurrent tonsillitis 55 mutated K ras 55 nmol L. 55 syncopal 55 GH deficiency 55 salivary cortisol 55 apolipoprotein B 55 dietary calcium intake 55 symptomatic carotid stenosis 55 colonic polyps 55 plasma glucose levels 55 visceral adiposity 55 transaminase levels 55 triglyceride concentration 55 flavonoid intake 55 pulmonary dysfunction 55 carotid artery intima media 55 completely resected 55 myocardial uptake 55 annualized relapse 55 endometrial carcinoma 55 symptom exacerbation 55 serum sodium 55 Symptom severity 55 cerebral oxygenation 55 LVEF 55 chorioamnionitis 55 cirrhotic patients 55 hypertension diabetes mellitus 55 Lp PLA 2 55 angiographically 55 umol L 55 macroalbuminuria 55 bilateral oophorectomy 55 neutrophil counts 55 elevated homocysteine 55 proteinuria 55 postoperative morbidity 55 visceral metastases 55 aminotransferase ALT 55 COPD exacerbation 55 fatal IHD 55 NSTEMI 55 CHADS2 55 operable breast cancer 55 acid suppressive medication 55 neoadjuvant radiation 55 cystatin C 55 fractional shortening 55 metachronous 55 rs# [002] 55 Hazard Ratio HR 55 carotid artery blockage 55 μg L 55 adenomatous polyps 55 fasting triglyceride levels 55 preserved ejection fraction 55 Reynolds Risk Score 55 subtrochanteric 55 debulking surgery 55 Secondary endpoints include 55 μg dl 55 histologic subtypes 55 serum lipid 55 RBC folate 55 locoregional control 55 PNH patients 55 ECG abnormalities 55 antiplatelet drugs 55 microvascular complications 55 #OHD 55 atherosclerotic vascular disease 55 asthma exacerbations 55 glomerular filtration 55 premenopausal 55 exhaled NO 55 ß blockers 55 cardiac dysfunction 55 cardiovascular hospitalizations 55 PCA3 scores 55 haematologic 55 serologically active patients 55 tPSA 55 nitrotyrosine 55 Multivariate analyzes 55 patients undergoing CABG 55 neurologic impairment 55 urinary N telopeptide 55 IBDQ 55 diabetes mellitus DM 55 androgen suppression 55 tirofiban 55 PREZISTA r arm 55 hemoglobin A1C 55 multivariate analysis 55 serum phosphate levels 55 plasma selenium 55 underwent CABG 55 tibolone 55 NIH CPSI 55 cotinine levels 55 IFN alfa 55 certolizumab 55 nonadherent 55 protein excretion 55 TAXUS Express Stent 55 myocardial reperfusion 55 achieved statistical significance 55 prognostic factors 55 noncardiovascular mortality 55 mmHg systolic 55 logistic regression analyzes 55 prostate carcinogenesis 55 serum phosphorous 55 onset atrial fibrillation 55 allogeneic HSCT 55 NIHSS 55 APOE genotype 55 inhibin B 55 hemodynamically significant 55 pancreatic adenocarcinoma 55 poorer prognosis 55 MADIT CRT trial 55 X ULN 55 invasive carcinomas 55 myocardial viability 55 carotid plaque 55 postoperative complications 55 BYSTOLIC 55 thyrotropin 55 upper gastrointestinal bleeding 55 mRNA expression 55 achieved CCyR 55 sodium excretion 55 Secondary endpoints 55 cerebrovascular events 55 pooled comparator 55 DAS# remission 55 stage IIIb IV 55 undetectable PSA 55 ARCOXIA 55 antiretroviral naive 55 hepatic insulin sensitivity 55 oxcarbazepine 55 mcg BID 55 LVSD 55 biphasic insulin aspart 55 prescribed statins 55 HBeAg 55 angiotensin II receptor blockers 55 darbepoetin alpha 55 EXJADE 55 -#.# log# 55 sleeve lobectomy 55 rebleeding 55 microbiologically evaluable 55 vaccinees 55 hyperphenylalaninemia HPA due 55 intravenous diuretics 55 hematopoietic cancers 55 Doxil ® 55 rizatriptan 55 R0 resection 55 idraparinux 55 P ≤ 55 CsA 55 IL#B 55 unmeasured factors 55 postoperative pulmonary 55 perinatal mortality 55 underwent liver transplantation 55 familial AF 55 asymptomatic PAD 55 Platelet counts 55 imatinib therapy 55 aspartate aminotransferase 55 subsyndromal 55 #mg/day [002] 55 % CI #.#-#.# [001] 55 cTnI 55 nonischemic cardiomyopathy 55 probiotic supplementation 55 lifetime abstainers 55 pravastatin therapy 55 urinary cortisol 55 spontaneous preterm delivery 55 Adjuvant chemotherapy 55 revascularized 55 VT VF 55 coronary stenoses 55 vertebral fracture 55 hippocampal volumes 55 HBeAg positive patients 55 SRBD 55 coagulation parameters 55 revascularization procedure 55 CIN2 + 55 fibrinolysis 54 #mg/day [001] 54 asthma exacerbation 54 Fasting plasma glucose 54 APTIVUS r 54 elevated troponin 54 Stroke Scale 54 discontinuations due 54 steroid dexamethasone 54 oncologic outcomes 54 neurologic progression 54 AVODART 54 neurodevelopmental outcomes 54 mg BID dose 54 mcg dL 54 Avandia Actos 54 glycemia 54 gene polymorphism 54 systolic hypertension 54 oblimersen 54 thiazide diuretics 54 corticosterone levels 54 Logistic regression 54 precancerous cervical 54 artery calcification 54 mutated KRAS 54 undetectable viral load 54 platelet inhibition 54 pg mL 54 median CD4 54 CHD coronary 54 bronchopulmonary dysplasia BPD 54 GSTP1 54 esophageal acid 54 antioxidant supplementation 54 Insulin sensitivity 54 non valvular atrial 54 SIDS infants 54 cilostazol 54 pretransplant 54 perinatal outcomes 54 BMI percentile 54 salpingo oophorectomy 54 serum leptin 54 postprocedure 54 elevated depressive symptoms 54 Secondary efficacy endpoints 54 aspirin clopidogrel 54 AST ALT 54 rheumatoid factor 54 hyperbilirubinemia 54 corrected QT interval 54 receiving VICTRELIS 54 hypoglycemic events 54 tHcy concentrations 54 eplerenone 54 nanograms milliliter 54 serum ferritin 54 gadolinium enhancing lesions 54 recurrent ischemic stroke 54 5-fluorouracil/leucovorin 54 HRQL 54 receiving ISENTRESS 54 HMG CoA reductase inhibitors 54 oral olanzapine 54 rs# [004] 54 serum insulin 54 LDL cholesterol concentrations 54 glycosylated hemoglobin 54 endometrial hyperplasia 54 del 5q MDS 54 dose statin therapy 54 exemestane 54 nmol L 54 HAM D# 54 -#.# ± [002] 54 XIENCE V PROMUS Stent 54 recurrent UTI 54 retransplantation 54 statin monotherapy 54 AOR = 54 antiarrhythmic medications 54 invasive ductal 54 clodronate 54 telomere lengths 54 treat NNT 54 serum LDL cholesterol 54 g dl 54 WOMAC scores 54 HGPIN 54 fasting plasma 54 Kaplan Meier 54 nulliparous women 54 dyslipidaemia 54 hepatocellular carcinomas 54 magnesium intake 54 antihypertensive drugs 54 symptomatic intracranial hemorrhage 54 de novo AML 54 diastolic hypertension 54 concomitant antibiotics 54 Radical prostatectomy 54 mEq L 54 VcMP 54 serum albumin 54 cTnT 54 Framingham Offspring Study 54 Depressive symptoms 54 Partial Responses 54 Charlson comorbidity index 54 fraction LVEF 54 histologically confirmed 54 lymph node involvement 54 hypoglycaemic episodes 54 Score DAS# 54 #dhTxB# 54 CDAI score 54 AGILECT R 54 adjuvant hormonal therapy 54 receiving prophylactic anticoagulation 54 serum cortisol 54 methotrexate monotherapy 54 lispro